Semjonow A, Hamm M, Rathert P
Department of Urology, Academic Hospital Düren, University of Aachen, FRG.
Eur Urol. 1992;21(3):200-5. doi: 10.1159/000474838.
Prostate-specific antigen (PSA) half-life calculated in 51 patients subsequent to radical prostatectomy was found to identify patients with residual disease earlier and more reliably than the criterion of not achieving undetectable PSA levels postoperatively. It is proposed that residual tumor affects the half-life by contributing to the serum level of PSA. When PSA half-life was calculated solely in potentially cured patients, we found a half-life of 1.5 days being considerably shorter than in the previous reports based on patient populations regardless of the outcome of disease in the follow-up.
对51例前列腺癌根治术后患者的前列腺特异性抗原（PSA）半衰期进行计算，结果发现，与术后未能达到PSA检测不出的标准相比，该指标能更早、更可靠地识别出有残留疾病的患者。有人提出，残留肿瘤通过影响PSA的血清水平来影响半衰期。当仅对可能已治愈的患者计算PSA半衰期时，我们发现其半衰期为1.5天，这比之前基于所有患者群体（无论随访中疾病结局如何）的报告结果要短得多。
